MX2022008130A - Derivado de insulina. - Google Patents
Derivado de insulina.Info
- Publication number
- MX2022008130A MX2022008130A MX2022008130A MX2022008130A MX2022008130A MX 2022008130 A MX2022008130 A MX 2022008130A MX 2022008130 A MX2022008130 A MX 2022008130A MX 2022008130 A MX2022008130 A MX 2022008130A MX 2022008130 A MX2022008130 A MX 2022008130A
- Authority
- MX
- Mexico
- Prior art keywords
- insulin
- pharmaceutical composition
- acylated insulin
- pharmaceutical formulation
- insulin derivative
- Prior art date
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title abstract 5
- 239000004026 insulin derivative Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 4
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 abstract 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 abstract 1
- -1 GLP-1 compound Chemical class 0.000 abstract 1
- FYZPCMFQCNBYCY-WIWKJPBBSA-N Insulin degludec Chemical compound CC[C@H](C)[C@H](NC(=O)CN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]1CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc3c[nH]cn3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC2=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H]([C@@H](C)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC(O)=O)C(O)=O)C(O)=O)NC1=O)[C@@H](C)O)[C@@H](C)CC FYZPCMFQCNBYCY-WIWKJPBBSA-N 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 108010050259 insulin degludec Proteins 0.000 abstract 1
- 229960004225 insulin degludec Drugs 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Se divulga una insulina acilada, una formulación farmacéutica de esta, una composición farmacéutica de esta con un compuesto GLP-1 de acción prolongada y un uso médico de la insulina acilada, la formulación farmacéutica y la composición farmacéutica. En comparación con la insulina degludec u otros derivados de la insulina, la insulina acilada tiene un efecto de farmacológico inesperado y significativamente mayor, una mayor duración de acción, una vida media in vivo más prolongada y una excelente biodisponibilidad, así como una mejor estabilidad física y química.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911398378 | 2019-12-30 | ||
| CN202011057926 | 2020-09-29 | ||
| PCT/CN2020/141023 WO2021136296A1 (zh) | 2019-12-30 | 2020-12-29 | 胰岛素衍生物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022008130A true MX2022008130A (es) | 2022-10-03 |
Family
ID=76687317
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022008130A MX2022008130A (es) | 2019-12-30 | 2020-12-29 | Derivado de insulina. |
| MX2022008174A MX2022008174A (es) | 2019-12-30 | 2020-12-29 | Derivado de insulina. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022008174A MX2022008174A (es) | 2019-12-30 | 2020-12-29 | Derivado de insulina. |
Country Status (10)
| Country | Link |
|---|---|
| US (5) | US20240025957A1 (es) |
| EP (3) | EP4086278A4 (es) |
| JP (3) | JP2023510206A (es) |
| KR (2) | KR20220121833A (es) |
| CN (12) | CN118420744A (es) |
| AU (2) | AU2020418205A1 (es) |
| BR (2) | BR112022013150A2 (es) |
| CA (2) | CA3166494A1 (es) |
| MX (2) | MX2022008130A (es) |
| WO (3) | WO2021136296A1 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023510218A (ja) * | 2019-12-30 | 2023-03-13 | ガン アンド リー ファーマスゥーティカルズ カンパニー リミテッド | 長時間作用型ｇｌｐ－１化合物 |
| WO2022159395A1 (en) | 2021-01-20 | 2022-07-28 | Viking Therapeutics, Inc. | Compositions and methods for the treatment of metabolic and liver disorders |
| US20240374692A1 (en) * | 2021-05-24 | 2024-11-14 | Sunshine Lake Pharma Co., Ltd. | A novel acylated insulin analog |
| AU2022300061A1 (en) * | 2021-06-25 | 2024-02-01 | Gan & Lee Pharmaceuticals Co., Ltd. | Acylated insulin-containing pharmaceutical composition |
| EP4259647A4 (en) | 2021-09-15 | 2025-03-26 | Viking Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC AND LIVER DISEASES |
| CN116162147B (zh) * | 2021-11-24 | 2023-10-03 | 成都奥达生物科技有限公司 | 一种长效胰岛素类似物 |
| WO2023143458A1 (zh) * | 2022-01-28 | 2023-08-03 | 甘李药业股份有限公司 | 酰化胰岛素 |
| CN120731085A (zh) * | 2023-03-02 | 2025-09-30 | 甘李药业股份有限公司 | 一种glp-1化合物的医药用途 |
| WO2024239961A1 (zh) * | 2023-05-24 | 2024-11-28 | 联邦生物科技(珠海横琴)有限公司 | 一种胰岛素衍生物及其应用 |
| CN116327890B (zh) * | 2023-05-29 | 2023-12-08 | 北京先为达生物科技有限公司 | 口服递送的组合物及其应用 |
| CN116789801B (zh) * | 2023-08-21 | 2023-11-14 | 南京赛诺生物技术有限公司 | 新型胰岛素衍生物及其用途 |
| WO2025077751A1 (zh) * | 2023-10-09 | 2025-04-17 | 甘李药业股份有限公司 | Glp-1肽组合物及其用途 |
| WO2025098457A1 (zh) * | 2023-11-07 | 2025-05-15 | 甘李药业股份有限公司 | 用于降糖的酰化胰岛素 |
| WO2025098502A1 (zh) * | 2023-11-08 | 2025-05-15 | 甘李药业股份有限公司 | 包含胰岛素衍生物的药物组合物的治疗用途 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ199391A (en) | 1981-01-02 | 1985-12-13 | Genentech Inc | Chimeric polypeptides comprising a proinsulin sequence,and preparation by recombinant dna technique;production of human insulin |
| DK58285D0 (da) | 1984-05-30 | 1985-02-08 | Novo Industri As | Peptider samt fremstilling og anvendelse deraf |
| PH25772A (en) | 1985-08-30 | 1991-10-18 | Novo Industri As | Insulin analogues, process for their preparation |
| DK336188D0 (da) | 1988-06-20 | 1988-06-20 | Nordisk Gentofte | Propeptider |
| JPH04502465A (ja) | 1988-12-23 | 1992-05-07 | ノボ ノルディスク アクティーゼルスカブ | ヒトインシュリン類似物質 |
| IL93282A (en) | 1989-02-09 | 1995-08-31 | Lilly Co Eli | Insulin analogues |
| KR100310122B1 (ko) | 1993-09-17 | 2002-04-24 | 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 | 아실화된인슐린 |
| AU1272295A (en) | 1993-12-17 | 1995-07-03 | Novo Nordisk A/S | Proinsulin-like compounds |
| US6500645B1 (en) | 1994-06-17 | 2002-12-31 | Novo Nordisk A/S | N-terminally extended proteins expressed in yeast |
| KR0150565B1 (ko) | 1995-02-15 | 1998-08-17 | 김정재 | 유전자 조환에 의한 사람 인슐린 전구체의 제조 및 이를 이용한 인슐린의 제조방법 |
| WO1996034882A1 (en) | 1995-05-05 | 1996-11-07 | Eli Lilly And Company | Single chain insulin with high bioactivity |
| EP2264065B1 (en) | 2003-08-05 | 2017-03-08 | Novo Nordisk A/S | Novel insulin derivatives |
| US8722620B2 (en) * | 2006-02-27 | 2014-05-13 | Novo Nordisk A/S | Insulin derivatives |
| ES2548393T3 (es) * | 2006-05-09 | 2015-10-16 | Novo Nordisk A/S | Derivado de insulina |
| WO2008015099A2 (en) | 2006-07-31 | 2008-02-07 | Novo Nordisk A/S | Pegylated, extended insulins |
| CN101743252A (zh) | 2007-07-16 | 2010-06-16 | 诺沃-诺迪斯克有限公司 | 蛋白酶稳定化的、peg化的胰岛素类似物 |
| CN101784562B (zh) * | 2007-08-15 | 2016-07-13 | 诺沃-诺迪斯克有限公司 | 具有酰基和亚烷基二醇部分的胰岛素类似物 |
| EP2178910B1 (en) * | 2007-08-15 | 2014-10-08 | Novo Nordisk A/S | Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids |
| US20100292133A1 (en) * | 2007-09-05 | 2010-11-18 | Novo Nordisk A/S | Truncated glp-1 derivaties and their therapeutical use |
| PT2254906T (pt) * | 2008-03-18 | 2017-01-03 | Novo Nordisk As | Análogos de insulina acilados, estabilizados contra proteases |
| JP6058646B2 (ja) * | 2011-06-15 | 2017-01-11 | ノヴォ ノルディスク アー／エス | 多置換インスリン |
| JP6153206B2 (ja) | 2011-12-15 | 2017-06-28 | シャンハイ ヘンルイ ファーマスーティカル カンパニー リミテッドＳｈａｎｇｈａｉ Ｈｅｎｇｒｕｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． | ヒト・インスリン類似体及びそのアシル化誘導体 |
| EP2869830B1 (en) * | 2012-07-09 | 2016-10-12 | Novo Nordisk A/S | Novel use of insulin derivatives |
| AR099569A1 (es) * | 2014-02-28 | 2016-08-03 | Novo Nordisk As | Derivados de insulina y los usos médicos de estos |
| CN105820233B (zh) | 2015-01-04 | 2021-06-15 | 甘李药业股份有限公司 | 一种胰岛素衍生物的制备方法 |
| WO2016119854A1 (en) * | 2015-01-29 | 2016-08-04 | Novo Nordisk A/S | Pharmaceutical composition for oral insulin administration comprising a tablet core and a polyvinyl alcohol coating |
| BR112018002416A2 (pt) * | 2015-08-25 | 2018-09-18 | Novo Nordisk As | derivados de insulina e seus usos médicos |
| JP7038042B2 (ja) * | 2015-08-27 | 2022-03-17 | ハルドール・トプサー・アクチエゼルスカベット | 高タップ密度のリチウム正極活物質、中間体および製造方法 |
| CN108463468B (zh) | 2016-08-02 | 2022-03-04 | 江苏恒瑞医药股份有限公司 | 一种人胰岛素或其类似物的酰化衍生物 |
| TWI700091B (zh) * | 2016-12-16 | 2020-08-01 | 丹麥商諾佛 儂迪克股份有限公司 | 含胰島素醫藥組成物 |
| JOP20190273A1 (ar) * | 2017-05-26 | 2019-11-24 | Lilly Co Eli | مركب إنسولين معالج بأسيل |
-
2020
- 2020-12-29 CA CA3166494A patent/CA3166494A1/en active Pending
- 2020-12-29 CN CN202410254905.5A patent/CN118420744A/zh active Pending
- 2020-12-29 CN CN202411112792.1A patent/CN118894922A/zh active Pending
- 2020-12-29 WO PCT/CN2020/141023 patent/WO2021136296A1/zh not_active Ceased
- 2020-12-29 KR KR1020227024018A patent/KR20220121833A/ko active Pending
- 2020-12-29 CN CN202410254314.8A patent/CN118420743A/zh active Pending
- 2020-12-29 US US17/758,108 patent/US20240025957A1/en active Pending
- 2020-12-29 BR BR112022013150A patent/BR112022013150A2/pt unknown
- 2020-12-29 CN CN202080091196.3A patent/CN114901682B/zh active Active
- 2020-12-29 CA CA3166495A patent/CA3166495A1/en active Pending
- 2020-12-29 WO PCT/CN2020/141018 patent/WO2021136293A1/zh not_active Ceased
- 2020-12-29 JP JP2022540767A patent/JP2023510206A/ja active Pending
- 2020-12-29 CN CN202410312489.XA patent/CN118480114A/zh active Pending
- 2020-12-29 US US17/758,089 patent/US20230126068A1/en active Pending
- 2020-12-29 AU AU2020418205A patent/AU2020418205A1/en active Pending
- 2020-12-29 MX MX2022008130A patent/MX2022008130A/es unknown
- 2020-12-29 WO PCT/CN2020/141056 patent/WO2021136302A1/zh not_active Ceased
- 2020-12-29 EP EP20908882.2A patent/EP4086278A4/en active Pending
- 2020-12-29 EP EP20910739.0A patent/EP4086280A4/en active Pending
- 2020-12-29 CN CN202410288928.8A patent/CN118206632A/zh active Pending
- 2020-12-29 CN CN202080091328.2A patent/CN114901683B/zh active Active
- 2020-12-29 KR KR1020227026305A patent/KR20220119730A/ko active Pending
- 2020-12-29 CN CN202411113751.4A patent/CN118772259A/zh active Pending
- 2020-12-29 CN CN202411113581.XA patent/CN118754967A/zh active Pending
- 2020-12-29 EP EP20910566.7A patent/EP4086279A4/en active Pending
- 2020-12-29 CN CN202410312576.5A patent/CN118666989A/zh active Pending
- 2020-12-29 CN CN202410286752.2A patent/CN118598978A/zh active Pending
- 2020-12-29 US US17/758,101 patent/US20240239862A1/en active Pending
- 2020-12-29 BR BR112022013009A patent/BR112022013009A2/pt unknown
- 2020-12-29 CN CN202080091153.5A patent/CN114901681B/zh active Active
- 2020-12-29 MX MX2022008174A patent/MX2022008174A/es unknown
- 2020-12-29 JP JP2022540871A patent/JP2023510219A/ja active Pending
- 2020-12-29 AU AU2020417892A patent/AU2020417892A1/en active Pending
-
2024
- 2024-09-18 US US18/889,097 patent/US20250032589A1/en not_active Abandoned
-
2025
- 2025-02-12 US US19/052,262 patent/US20250228919A1/en not_active Abandoned
- 2025-07-31 JP JP2025128114A patent/JP2025161829A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022008130A (es) | Derivado de insulina. | |
| CY1123597T1 (el) | Σκευασματα ινσουλινης για γρηγορη προσληψη | |
| PE20181494A1 (es) | Conjugado persistente de triple activador que activa el receptor de glucagon, glp-1 u gip | |
| CY1120564T1 (el) | Υδατικα εναιωρηματα tmc278 | |
| ZA201902053B (en) | Pharmaceutical composition | |
| MX378856B (es) | Composiciones farmaceuticas parenterales acuosas estables de peptidos insulinotropicos. | |
| BR112018008880A8 (pt) | composto 7-(tiazol-5-il) pirrolopirimidina como agonista de tlr7 | |
| CY1119582T1 (el) | Υδατικα παρασκευασματα ινσουλινης, που περιεχουν μεθειονινη | |
| CY1118735T1 (el) | Παραγωγα βενζιμιδαζολο-προλινης | |
| NI201200086A (es) | Composición farmacéutica que comprende un agonista de glp - 1 y metionina | |
| DE602006014990D1 (de) | Intranasale verabreichung von schnell wirkendem insulin | |
| UY36943A (es) | PIRAZOLO[3,4-b]PIRIDIN-6-CARBOXAMIDAS N-SULFONILADAS Y MÉTODO PARA SU USO | |
| PE20180449A1 (es) | Derivado de glucagon y una composicion que comprende un conjugado de accion prolongada del mismo | |
| NZ707160A (en) | A stable aqueous composition comprising human insulin or an analogue or derivative thereof | |
| PE20220017A1 (es) | Inhibidores del kcnt1 y metodos de uso | |
| BRPI0819719B8 (pt) | compostos de inibição de dipeptidil peptidase-iv, métodos de preparação dos mesmos, e preparações farmacêuticas contendo os mesmos como agente ativo | |
| BR112016001544A2 (pt) | composições farmacêuticas para injeção intraocular compreendendo agentes anti-bacteriano e anti-inflamatório, seu método de preparação, kit farmacêutico e uso dos referidos agentes no preparo das referidas composições farmacêuticas | |
| EA201990501A1 (ru) | Фармацевтическая композиция | |
| MX2020011007A (es) | Derivado de péptido-1 (glp-1) similar al glucagón acilado. | |
| AR059097A1 (es) | Tratamiento a largo plazo de la infeccion por vih | |
| MX2019003099A (es) | Composicion farmaceutica. | |
| MX387725B (es) | Composición farmacéutica. | |
| CO2022004978A2 (es) | Inhibidor de irak y método de preparación para el mismo y uso del mismo | |
| MX2019003097A (es) | Composicion farmaceutica. | |
| CO2019003632A2 (es) | Formulaciones de buprenorfina de liberación sostenida |